Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial.
Tiessen RG, Kennedy CA, Keller BT, Levin N, Acevedo L, Gedulin B, van Vliet AA, Dorenbaum A, Palmer M. Tiessen RG, et al. Among authors: keller bt. BMC Gastroenterol. 2018 Jan 5;18(1):3. doi: 10.1186/s12876-017-0736-0. BMC Gastroenterol. 2018. PMID: 29304731 Free PMC article. Clinical Trial.
Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.
Miethke AG, Zhang W, Simmons J, Taylor AE, Shi T, Shanmukhappa SK, Karns R, White S, Jegga AG, Lages CS, Nkinin S, Keller BT, Setchell KD. Miethke AG, et al. Among authors: keller bt. Hepatology. 2016 Feb;63(2):512-23. doi: 10.1002/hep.27973. Epub 2015 Aug 21. Hepatology. 2016. PMID: 26172874 Free PMC article.
Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 2).
Huang HC, Tremont SJ, Lee LF, Keller BT, Carpenter AJ, Wang CC, Banerjee SC, Both SR, Fletcher T, Garland DJ, Huang W, Jones C, Koeller KJ, Kolodziej SA, Li J, Manning RE, Mahoney MW, Miller RE, Mischke DA, Rath NP, Reinhard EJ, Tollefson MB, Vernier WF, Wagner GM, Rapp SR, Beaudry J, Glenn K, Regina K, Schuh JR, Smith ME, Trivedi JS, Reitz DB. Huang HC, et al. Among authors: keller bt. J Med Chem. 2005 Sep 8;48(18):5853-68. doi: 10.1021/jm0402162. J Med Chem. 2005. PMID: 16134951
Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 1).
Tremont SJ, Lee LF, Huang HC, Keller BT, Banerjee SC, Both SR, Carpenter AJ, Wang CC, Garland DJ, Huang W, Jones C, Koeller KJ, Kolodziej SA, Li J, Manning RE, Mahoney MW, Miller RE, Mischke DA, Rath NP, Fletcher T, Reinhard EJ, Tollefson MB, Vernier WF, Wagner GM, Rapp SR, Beaudry J, Glenn K, Regina K, Schuh JR, Smith ME, Trivedi JS, Reitz DB. Tremont SJ, et al. Among authors: keller bt. J Med Chem. 2005 Sep 8;48(18):5837-52. doi: 10.1021/jm040215+. J Med Chem. 2005. PMID: 16134950
1-[4-[4[(4R,5R)-3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]butyl]-4-aza-1-azoniabicyclo[2.2.2]octane methanesulfonate (SC-435), an ileal apical sodium-codependent bile acid transporter inhibitor alters hepatic cholesterol metabolism and lowers plasma low-density lipoprotein-cholesterol concentrations in guinea pigs.
West KL, Ramjiganesh T, Roy S, Keller BT, Fernandez ML. West KL, et al. Among authors: keller bt. J Pharmacol Exp Ther. 2002 Oct;303(1):293-9. doi: 10.1124/jpet.102.038711. J Pharmacol Exp Ther. 2002. PMID: 12235263
46 results